JP2018509889A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509889A5 JP2018509889A5 JP2017540249A JP2017540249A JP2018509889A5 JP 2018509889 A5 JP2018509889 A5 JP 2018509889A5 JP 2017540249 A JP2017540249 A JP 2017540249A JP 2017540249 A JP2017540249 A JP 2017540249A JP 2018509889 A5 JP2018509889 A5 JP 2018509889A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- heavy chain
- mature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 5
- 108010071690 Prealbumin Proteins 0.000 claims 8
- 102000009190 Transthyretin Human genes 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 206010002022 amyloidosis Diseases 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000003403 autonomic nervous system Anatomy 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000005252 bulbus oculi Anatomy 0.000 claims 1
- 239000013068 control sample Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Images
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021072547A JP7219928B2 (ja) | 2015-01-28 | 2021-04-22 | 抗トランスサイレチン抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562109001P | 2015-01-28 | 2015-01-28 | |
| US62/109,001 | 2015-01-28 | ||
| US201562266557P | 2015-12-11 | 2015-12-11 | |
| US62/266,557 | 2015-12-11 | ||
| PCT/IB2016/050414 WO2016120809A1 (en) | 2015-01-28 | 2016-01-28 | Anti-transthyretin antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021072547A Division JP7219928B2 (ja) | 2015-01-28 | 2021-04-22 | 抗トランスサイレチン抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509889A JP2018509889A (ja) | 2018-04-12 |
| JP2018509889A5 true JP2018509889A5 (enExample) | 2019-03-07 |
| JP6875280B2 JP6875280B2 (ja) | 2021-05-26 |
Family
ID=55361912
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540249A Active JP6875280B2 (ja) | 2015-01-28 | 2016-01-28 | 抗トランスサイレチン抗体 |
| JP2021072547A Active JP7219928B2 (ja) | 2015-01-28 | 2021-04-22 | 抗トランスサイレチン抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021072547A Active JP7219928B2 (ja) | 2015-01-28 | 2021-04-22 | 抗トランスサイレチン抗体 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20160257736A1 (enExample) |
| EP (1) | EP3250594B1 (enExample) |
| JP (2) | JP6875280B2 (enExample) |
| KR (1) | KR102619359B1 (enExample) |
| CN (1) | CN107428822B (enExample) |
| AU (1) | AU2016210887B2 (enExample) |
| CA (1) | CA2974911A1 (enExample) |
| CO (1) | CO2017008469A2 (enExample) |
| CU (1) | CU24532B1 (enExample) |
| EA (1) | EA036048B1 (enExample) |
| ES (1) | ES2905311T3 (enExample) |
| MX (1) | MX391789B (enExample) |
| MY (1) | MY193674A (enExample) |
| PE (1) | PE20180200A1 (enExample) |
| SA (1) | SA517381991B1 (enExample) |
| SG (1) | SG11201706125QA (enExample) |
| TW (2) | TWI781507B (enExample) |
| WO (1) | WO2016120809A1 (enExample) |
| ZA (1) | ZA201705662B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| TWI781507B (zh) * | 2015-01-28 | 2022-10-21 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| EP3478715A2 (en) * | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| WO2018007922A2 (en) * | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| WO2018007924A2 (en) * | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| AU2018338790B2 (en) | 2017-09-29 | 2022-09-15 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized TTR locus and methods of use |
| PE20210042A1 (es) * | 2017-10-06 | 2021-01-08 | Prothena Biosciences Ltd | Metodos para detectar transtiretina |
| MX2020003041A (es) * | 2017-10-06 | 2020-10-05 | Prothena Biosciences Ltd | Anticuerpos anti-transtiretina. |
| CU20200042A7 (es) | 2017-11-29 | 2021-03-11 | Prothena Biosciences Ltd | Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina |
| KR20220016869A (ko) * | 2019-06-04 | 2022-02-10 | 리제너론 파마슈티칼스 인코포레이티드 | 베타-슬립 돌연변이를 갖는 인간화 ttr 좌위를 포함하는 비-인간 동물 및 사용 방법 |
| CN112816453B (zh) * | 2021-02-09 | 2022-07-08 | 黑龙江大学 | 蛋白在预测药物性能上的应用 |
| WO2025125544A1 (en) | 2023-12-15 | 2025-06-19 | Novo Nordisk A/S | Stable liquid formulations |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル，インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| DE69329974T2 (de) | 1992-12-04 | 2001-07-19 | Medical Research Council, London | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5877218A (en) | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| ATE490518T1 (de) | 1999-02-05 | 2010-12-15 | Samsung Electronics Co Ltd | Verfahren und vorrichtung zum wiederauffinden von texturbildern |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| EP2298809A3 (en) | 2001-07-12 | 2012-02-15 | FOOTE, Jefferson | Super humanized antibodies |
| ES2289174T3 (es) | 2001-12-28 | 2008-02-01 | Amgen Fremont Inc. | Anticuerpos contra el antigeno muc-18. |
| DE50308030D1 (de) | 2002-11-29 | 2007-10-04 | Boehringer Ingelheim Pharma | Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen |
| DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| PT1820022E (pt) | 2004-11-10 | 2009-08-05 | Boehringer Ingelheim Pharma | Utilização de análise por citometria de fluxo para optimizar estratégias de conservação de bancos de células cho |
| EP2808020A1 (en) | 2006-04-21 | 2014-12-03 | The Government Of The United States, As Represented by The Secretary Of Health And Human Services | Beta-Amyloid Pet Imaging Agents |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| ES2523915T5 (es) | 2006-12-01 | 2022-05-26 | Seagen Inc | Agentes de unión a la diana variantes y usos de los mismos |
| DK2126093T3 (da) | 2007-03-02 | 2013-01-07 | Boehringer Ingelheim Pharma | Forbedring af proteinfremstilling |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| WO2010030203A1 (en) * | 2008-09-09 | 2010-03-18 | Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. | Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr |
| US9534048B2 (en) * | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
| JP2016514091A (ja) * | 2013-02-08 | 2016-05-19 | ミスフォールディング ダイアグノスティクス， インコーポレイテッド | トランスサイレチン抗体およびその使用 |
| TWI781507B (zh) * | 2015-01-28 | 2022-10-21 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
-
2016
- 2016-01-27 TW TW110100084A patent/TWI781507B/zh active
- 2016-01-27 TW TW105102534A patent/TWI718121B/zh not_active IP Right Cessation
- 2016-01-28 KR KR1020177023748A patent/KR102619359B1/ko active Active
- 2016-01-28 JP JP2017540249A patent/JP6875280B2/ja active Active
- 2016-01-28 AU AU2016210887A patent/AU2016210887B2/en active Active
- 2016-01-28 ES ES16704940T patent/ES2905311T3/es active Active
- 2016-01-28 CA CA2974911A patent/CA2974911A1/en active Pending
- 2016-01-28 US US15/009,666 patent/US20160257736A1/en not_active Abandoned
- 2016-01-28 CU CU2017000096A patent/CU24532B1/es unknown
- 2016-01-28 SG SG11201706125QA patent/SG11201706125QA/en unknown
- 2016-01-28 MX MX2017009804A patent/MX391789B/es unknown
- 2016-01-28 CN CN201680015800.8A patent/CN107428822B/zh active Active
- 2016-01-28 PE PE2017001286A patent/PE20180200A1/es unknown
- 2016-01-28 WO PCT/IB2016/050414 patent/WO2016120809A1/en not_active Ceased
- 2016-01-28 EP EP16704940.2A patent/EP3250594B1/en active Active
- 2016-01-28 MY MYPI2017702749A patent/MY193674A/en unknown
- 2016-01-28 EA EA201791711A patent/EA036048B1/ru unknown
-
2017
- 2017-07-26 SA SA517381991A patent/SA517381991B1/ar unknown
- 2017-08-21 ZA ZA2017/05662A patent/ZA201705662B/en unknown
- 2017-08-22 CO CONC2017/0008469A patent/CO2017008469A2/es unknown
-
2021
- 2021-04-22 JP JP2021072547A patent/JP7219928B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018509889A5 (enExample) | ||
| JP2018506277A5 (enExample) | ||
| JP2018510617A5 (enExample) | ||
| CN110291109B (zh) | 人程序性死亡受体pd-1的单克隆抗体及其片段 | |
| JP5906233B2 (ja) | 抗ＥｒｂＢ３抗体 | |
| JP7663977B2 (ja) | 抗ｐｄ―ｌ１抗体およびその用途 | |
| JP2017535257A5 (enExample) | ||
| JP2019530427A5 (enExample) | ||
| JP2020536532A5 (enExample) | ||
| JP2019525728A5 (enExample) | ||
| JP2020514277A5 (enExample) | ||
| JP2018512175A5 (enExample) | ||
| JP2013508292A5 (enExample) | ||
| JP2018527919A5 (enExample) | ||
| RU2016129113A (ru) | Антитела к pd-1 собак | |
| JP2013544492A5 (enExample) | ||
| RU2015136078A (ru) | Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний | |
| JP2019522961A5 (enExample) | ||
| JP2014534806A5 (enExample) | ||
| JP2019527194A5 (enExample) | ||
| JP2014503205A5 (enExample) | ||
| JP2017537082A5 (enExample) | ||
| US12173081B2 (en) | CD19/CD38 multispecific antibodies | |
| TW201134489A (en) | Basigin binding proteins | |
| JP2020513759A5 (enExample) |